Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Foamix Pharmaceuticals Ltd. | exhibit_99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): October 1, 2018
FOAMIX PHARMACEUTICALS LTD.
(Translation of registrant's name into English)
|
Israel
|
001-36621
|
N/A
|
|||
|
(State or other jurisdiction
of incorporation) |
(Commission File Number)
|
(IRS Employer
Identification No.) |
|||
|
2 Holzman Street,
Weizmann Science Park
|
|||||
|
Rehovot, Israel
|
7670402
|
||||
|
(Address of principal executive offices)
|
(Zip Code)
|
||||
|
+972-8-9316233
|
|||||
|
(Registrant's telephone number, including area code)
|
|||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure.
On October 1, 2018, Foamix Pharmaceuticals Ltd. (the "Company") issued a press release entitled, "Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne."
On October 2, 2018, the Company will present these additional topline results along with an overall corporate update at the Cantor Fitzgerald Global Healthcare Conference. Updated presentation materials are available on the Company's website under "Investors – Events and Presentations" at www.foamix.com.
The press release is being furnished hereto as Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
Description
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 1, 2018
|
FOAMIX PHARMACEUTICALS LTD.
|
||
|
By:
|
/s/ Ilan Hadar
|
|
|
Ilan Hadar
|
||
|
Chief Financial Officer & Country Manager
|
||